PharmaS’ newest strategic acquisition lands in Spain as it acquires majority stake in Madrid-based MABO-FARMA.

Founded back in 1996 in Madrid, MABO-FARMA is one of the fastest growing companies in the Spanish retail generics market. Majority of revenue comes from its Rx business; however, the company is actively growing its consumer healthcare and OTC operations. Along with a portfolio of more than 200 SKUs, one of MABO-FARMA’s greatest strengths is market excellence as it counts over sixty customer-facing staff, geographically covering all of Spain, including Balearic and Canary Islands.

Key synergies between PharmaS and MABO-FARMA come from MABO’s deep understanding of Spanish retail pharma market and PharmaS’ strong track record in the hospital market, strong supply partnerships with top-tier global pharma manufacturers and a large portfolio of consumer healthcare products developed and manufactured in its own facilities in Croatia and Serbia. With this acquisition, PharmaS will have reached 100 million EUR in annual revenue with over 150 staff in commercial operations covering SEE markets and Spain.

Entry into the Spanish market is just the beginning of PharmaS’ five-year strategic plan, which is further expansion into a number of Western European markets. We will continue to build PharmaS as a pan-European pharma company focused on commercialization of drugs, utilizing and further developing our partnership network.  What is especially exciting is that going global presents a great deal of developmental opportunities for all of our employees who want international experience. – said Jerko Jakšić, PharmaS CEO.

PharmaS was founded in 2008 in Zagreb, Croatia. It is present in most SEE markets and currently has operations across seven countries. Its pharma business includes a vast portfolio of Rx retail and hospital products, as well as OTC drugs. In addition, PharmaS is a leading player in the Adria region in consumer healthcare, having acquired Dietpharm portfolio back in 2019.